Cell Cryopreservation Consumables MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy Cryoprotectant TypeBy Container MaterialBy Fill Volume / CapacityBy Product GradeBy Application / Cell TypeBy End UserBy Sales / Distribution Channel

Cell cryopreservation consumables are the media, containers and ancillary products used to freeze, store and thaw living cells, tissues and other biospecimens without destroying their viability. The category spans cryoprotectant media formulated to protect cells during freezing, and the vials, bags, tubes, boxes, racks, labels and closures that hold and identify a sample through long-term cryogenic storage. Buyers include biopharmaceutical and cell therapy manufacturers, academic and clinical research laboratories, biobanks, fertility clinics and blood banks, each qualifying a specific combination of media and container for its own cell type and process.

The global cell cryopreservation consumables market is valued at USD 5.15 billion in 2025 and is set to reach USD 13.29 billion by 2034, a compound annual growth rate of 11.11% across the 2026-2034 forecast period. The study tracks the market across USD 3.65 billion in 2020, USD 4.92 billion in 2024, USD 5.72 billion in 2026 and USD 8.7 billion in 2030.

On the product type axis, growth rates run from 9.5% for Cryogenic Tubes & Straws up to 13.52% for Cryobags / Freezing Bags. Cryopreservation Media carries the volume: USD 1.65 billion and 32% of revenue in 2025, USD 4.39 billion and 33% in 2034. The lines gaining share are Cryopreservation Media and Cryobags / Freezing Bags. Cryovials / Cryogenic Vials, Cryogenic Tubes & Straws, Cryoboxes, Racks & Storage Systems, Labels & Identification Systems and Caps, Closures & Seals lose share without losing revenue.

The cryoprotectant type split puts DMSO-Based Formulations first, at USD 2.83 billion and 55% of revenue in 2025, rising to USD 6.38 billion and 48% in 2034. Serum-Free / Xeno-Free Formulations grows faster at 17.35% against 9.46%, moving from 8% of revenue to 13% by 2034. It cuts the same total as the product type axis from a different commercial angle, so revenue does not add across the two.

The regional order runs from North America at 43% of 2025 revenue down to Middle East and Africa at 3%. North America is worth USD 2.21 billion in 2025 and USD 5.32 billion in 2034; Europe, second at 25%, moves from USD 1.29 billion to USD 3.06 billion. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

The 2025 total is a triangulation of published figures and category proxies, short of a directly sourced total. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, eight product type lines and eight segmentation axes across a fifteen-year window.

• A forecast-period rate of 11.11% takes the market from USD 5.15 billion in 2025 to USD 13.29 billion in 2034, against 7.13% recorded over the 2020-2025 historical period.
• The largest line by product type is Cryopreservation Media, worth USD 1.65 billion and 32% of revenue in 2025, rising to USD 4.39 billion and 33% by 2034.
• At 13.52%, Cryobags / Freezing Bags grows faster than any other product type line, moving from USD 0.72 billion and 14% of revenue in 2025 to USD 2.26 billion and 17% in 2034.
• The bull case puts 2034 revenue at USD 14.73 billion and the bear case at USD 11.5 billion, either side of the USD 13.29 billion base case, each with its own stated assumption in the full report.
• 43% of 2025 revenue is generated in North America, worth USD 2.21 billion and rising to USD 5.32 billion by 2034; Middle East and Africa is smallest at 3%.
• 77.8% of North America's base-year revenue comes from the United States alone: USD 1.72 billion in 2025, rising to USD 4.15 billion by 2034, which is why it is that region's worked example.
• Every line on all eight segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

The global cell cryopreservation consumables market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 11.11% rate carrying the total.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.

Cryobags / Freezing Bags outpaces Cryogenic Tubes & Straws. 13.52% against 9.5%: that gap, between Cryobags / Freezing Bags and Cryogenic Tubes & Straws, is the largest on the product type axis. Shares follow: 14% to 17% for Cryobags / Freezing Bags, 8% to 7% for Cryogenic Tubes & Straws. The revenue figures behind that are USD 0.72 billion to USD 2.26 billion and USD 0.41 billion to USD 0.93 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

The regional balance moves. Asia Pacific moves from 24% of revenue in 2025 to 28% in 2034, worth USD 1.24 billion rising to USD 3.72 billion; Latin America moves from 5% of revenue in 2025 to 5.5% in 2034, worth USD 0.26 billion rising to USD 0.73 billion; Middle East and Africa moves from 3% of revenue in 2025 to 3.5% in 2034, worth USD 0.15 billion rising to USD 0.47 billion. Share moves off the others in turn: North America at 43% moving to 40%, Europe at 25% moving to 23%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Fifteen years without a discontinuity. Reading the series: USD 3.65 billion in 2020, USD 4.92 billion in 2024, USD 5.15 billion in 2025, USD 5.72 billion in 2026, USD 8.7 billion in 2030 and USD 13.29 billion in 2034. The forecast rate of 11.11% sits against 7.13% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.

Cryobags / Freezing Bags carries the market's growth rate

Separate the 11.11% into its parts and three show up: an already-large base compounding, the product type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 11.5 billion by 2034, against USD 13.29 billion in the base case

What the bull case turns on

Revenue is concentrated in Cryopreservation Media

North America holds 43% of the global cell cryopreservation consumables market in 2025, worth USD 2.21 billion rising to USD 5.32 billion in 2034. Among the five regions it ranks first by revenue in both years.

Its share moves to 40% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the product type split tracks the global one; 32% of 2025 revenue in Cryopreservation Media, fastest growth of 13.52% in Cryobags / Freezing Bags. Per-axis and per-country detail for North America sits in the full report.

USD 1.72 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 4.15 billion by 2034. Carrying 77.8% of the region in the base year, it sets North America's direction instead of merely contributing to it. Set against USD 2.21 billion and USD 5.32 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Cryopreservation Media at 32% of 2025 revenue, easing to 33% by 2034, and the fastest is Cryobags / Freezing Bags at 13.52%, from 14% to 17%. Its 77.8% weight in North America means those movements carry straight into the regional totals. Per-product type revenue for the United States appears on its own in the full report.

The Food and Drug Administration oversees cell cryopreservation consumables, treating cryopreservation media, freezing bags, and vials as medical devices under the Federal Food, Drug, and Cosmetic Act. Products intended for use in manufacturing human cellular and tissue-based products fall under the agency's framework for such materials, requiring donor eligibility safeguards and process validation from the supplier. Devices used more broadly in laboratory or clinical settings are classified according to risk, with premarket notification required for higher-risk formulations. Suppliers must register their establishments, list their devices, and conform to the FDA's quality system regulation for manufacturing controls. Labelling must state intended use, storage conditions, and lot traceability, since a cryopreserved sample's viability depends on chain-of-custody records the regulator expects to be verifiable.

Competition in the United States runs between the suppliers this study tracks: Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Sartorius AG, BioLife Solutions, Inc., Corning Incorporated, STEMCELL Technologies Inc., Lonza Group Ltd., Cytiva (Danaher Corporation), Takara Bio Inc., FUJIFILM Irvine Scientific, Inc., PromoCell GmbH, Saint-Gobain Life Sciences, Charter Medical, Ltd., OriGen Biomedical, Inc., Macopharma S.A., Avantor, Inc., Cardinal Health, Inc., HiMedia Laboratories Pvt. Ltd., Pluristyx, Inc., Cook Regentec LLC, Instant Systems, Inc., American Fluoroseal Corporation and GE HealthCare Technologies Inc.. The commercially relevant division is 32% of 2025 revenue in Cryopreservation Media, where the volume is, against 13.52% growth in Cryobags / Freezing Bags, where share moves. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 18.1% of regional revenue and 7.8% of the global total, worth USD 0.4 billion in 2025 and USD 0.96 billion by 2034.

Europe holds 25% of the global cell cryopreservation consumables market in 2025, worth USD 1.29 billion and reaches USD 3.06 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Share settles at 23% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the product type split tracks the global one; 32% of 2025 revenue in Cryopreservation Media, fastest growth of 13.52% in Cryobags / Freezing Bags. Per-axis and per-country detail for Europe sits in the full report.

Germany is the largest market within Europe, generating USD 0.39 billion in 2025 and projected to reach USD 0.92 billion by 2034. It accounts for 30.2% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 1.29 billion in 2025 and USD 3.06 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The product type pattern in Germany is the global one: 32% of 2025 revenue in Cryopreservation Media, 33% by 2034, against 13.52% growth in Cryobags / Freezing Bags taking it from 14% to 17%. With 30.2% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by product type for Germany is reported separately in the full report.

In Germany, cell cryopreservation consumables are regulated under the European Union's Medical Device Regulation, transposed into national oversight by the Federal Institute for Drugs and Medical Devices. Manufacturers must carry out a conformity assessment appropriate to the product's risk class, affix the CE mark, and maintain a quality management system consistent with the harmonised standard for medical device manufacturing. Where a product is derived from or intended for use with human tissue, the national transposition of the EU Tissue and Cells framework adds further obligations around traceability and donor safety. Labelling must be presented in German, state storage and handling conditions, and carry a unique device identifier so that a batch can be traced back through the cold chain to its point of manufacture.

Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Sartorius AG, BioLife Solutions, Inc., Corning Incorporated, STEMCELL Technologies Inc., Lonza Group Ltd., Cytiva (Danaher Corporation), Takara Bio Inc., FUJIFILM Irvine Scientific, Inc., PromoCell GmbH, Saint-Gobain Life Sciences, Charter Medical, Ltd., OriGen Biomedical, Inc., Macopharma S.A., Avantor, Inc., Cardinal Health, Inc., HiMedia Laboratories Pvt. Ltd., Pluristyx, Inc., Cook Regentec LLC, Instant Systems, Inc., American Fluoroseal Corporation and GE HealthCare Technologies Inc. are the suppliers covered in Germany. The commercially relevant division is 32% of 2025 revenue in Cryopreservation Media, where the volume is, against 13.52% growth in Cryobags / Freezing Bags, where share moves. The commercial size of that position is USD 1.29 billion in 2025 and USD 3.06 billion by 2034, 25% of the global total in the base year.

Within Europe, the United Kingdom accounts for 24% of regional revenue and 6% of the global total, worth USD 0.31 billion in 2025 and USD 0.73 billion by 2034.

France is sized at USD 0.23 billion in 2025, rising to USD 0.55 billion by 2034; 4.5% of global revenue and 17.8% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

24% of the global cell cryopreservation consumables market sits in Asia Pacific in 2025, worth USD 1.24 billion and reaches USD 3.72 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

Its share rises to 28% over the forecast period, because it outgrows the market's 11.11%; the revenue added here is disproportionate to where the region started.

Within the region the product type split tracks the global one; 32% of 2025 revenue in Cryopreservation Media, fastest growth of 13.52% in Cryobags / Freezing Bags. The full report breaks Asia Pacific out along every axis and by country.

USD 0.42 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 1.26 billion by 2034. At 33.9% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 1.24 billion in 2025 and USD 3.72 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

China buys along the same lines as the market globally; Cryopreservation Media first at 32% of 2025 revenue and 33% in 2034, Cryobags / Freezing Bags fastest at 13.52% on a share moving from 14% to 17%. Because the country carries 33.9% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. China carries its own product type breakdown in the full report.

China regulates cell cryopreservation consumables through the National Medical Products Administration, which classifies laboratory and clinical consumables according to the national medical device classification catalogue. Depending on intended use, a supplier must obtain either a filing or a full registration certificate before the product can be marketed, with higher-risk items intended for cell therapy manufacturing subject to closer technical review. Domestic and imported products alike must meet the relevant national standards for medical device materials and sterility, and labelling must be presented in Chinese, stating storage temperature, shelf life, and intended application. Where the consumable is used in the processing of human cells for therapeutic purposes, additional oversight from the National Health Commission applies to the broader cell-handling process.

Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Sartorius AG, BioLife Solutions, Inc., Corning Incorporated, STEMCELL Technologies Inc., Lonza Group Ltd., Cytiva (Danaher Corporation), Takara Bio Inc., FUJIFILM Irvine Scientific, Inc., PromoCell GmbH, Saint-Gobain Life Sciences, Charter Medical, Ltd., OriGen Biomedical, Inc., Macopharma S.A., Avantor, Inc., Cardinal Health, Inc., HiMedia Laboratories Pvt. Ltd., Pluristyx, Inc., Cook Regentec LLC, Instant Systems, Inc., American Fluoroseal Corporation and GE HealthCare Technologies Inc. are the suppliers covered in China. Volume sits in Cryopreservation Media at 32% of 2025 revenue; movement sits in Cryobags / Freezing Bags at 13.52% growth. That makes Asia Pacific a 24% share of 2025 global revenue, USD 1.24 billion rising to USD 3.72 billion, for any supplier deciding where to concentrate.

5.2% of global revenue is generated in Japan; USD 0.27 billion in 2025, reaching USD 0.82 billion in 2034, and 21.8% of Asia Pacific.

3.3% of global revenue is generated in India; USD 0.17 billion in 2025, reaching USD 0.52 billion in 2034, and 13.7% of Asia Pacific.

5% of the global cell cryopreservation consumables market sits in Latin America in 2025, worth USD 0.26 billion and reaches USD 0.73 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 5.5%, on growth above the market's own 11.11%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Segment composition follows the global pattern: Cryopreservation Media largest at 32% of 2025 revenue, Cryobags / Freezing Bags fastest at 13.52%. Latin America is reported axis by axis and country by country in the full study.

The largest single market in Latin America is Brazil, at USD 0.14 billion in 2025 and USD 0.4 billion in 2034. Its 53.8% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 0.26 billion and USD 0.73 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in Brazil follows the product type mix reported at global level: Cryopreservation Media is the largest line at 32% of 2025 revenue, moving to 33% by 2034, while Cryobags / Freezing Bags grows fastest at 13.52% and takes its share from 14% to 17%. Its 53.8% weight in Latin America means those movements carry straight into the regional totals. Per-product type revenue for Brazil appears on its own in the full report.

Brazil's health regulatory agency, ANVISA, oversees cell cryopreservation consumables as medical devices, requiring notification or full registration depending on the product's assigned risk class before it can be sold. Manufacturers and importers must hold a valid operating authorisation, and higher-risk products intended for use with human cells or tissue for therapeutic purposes fall under the agency's specific framework for cellular therapy products, which layers on additional requirements around donor traceability and processing controls. Conformity with the national standards adopted for medical device quality and sterility is mandatory, and labelling must appear in Portuguese, disclosing storage conditions, expiry, and the product's registration status with the agency so that a purchasing hospital or laboratory can confirm it is legally marketed.

In Brazil the field is Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Sartorius AG, BioLife Solutions, Inc., Corning Incorporated, STEMCELL Technologies Inc., Lonza Group Ltd., Cytiva (Danaher Corporation), Takara Bio Inc., FUJIFILM Irvine Scientific, Inc., PromoCell GmbH, Saint-Gobain Life Sciences, Charter Medical, Ltd., OriGen Biomedical, Inc., Macopharma S.A., Avantor, Inc., Cardinal Health, Inc., HiMedia Laboratories Pvt. Ltd., Pluristyx, Inc., Cook Regentec LLC, Instant Systems, Inc., American Fluoroseal Corporation and GE HealthCare Technologies Inc.. Cryopreservation Media, at 32% of 2025 revenue, is where the volume sits, and Cryobags / Freezing Bags, growing at 13.52%, is where position changes hands over the forecast period. Weighting toward Latin America means competing for 5% of 2025 global revenue, a base of USD 0.26 billion moving to USD 0.73 billion across the forecast period.

Within Latin America, Mexico accounts for 26.9% of regional revenue and 1.4% of the global total, worth USD 0.07 billion in 2025 and USD 0.18 billion by 2034.

3% of the global cell cryopreservation consumables market sits in Middle East and Africa in 2025, worth USD 0.15 billion on the way to USD 0.47 billion by 2034. Among the five regions it ranks fifth by revenue in both years.

Its share rises to 3.5% over the forecast period, so the region grows faster than the market's 11.11% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the product type split tracks the global one; 32% of 2025 revenue in Cryopreservation Media, fastest growth of 13.52% in Cryobags / Freezing Bags. The full report breaks Middle East and Africa out along every axis and by country.

33.3% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.05 billion, rising to USD 0.14 billion by 2034. Its 33.3% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Against regional totals of USD 0.15 billion in 2025 and USD 0.47 billion in 2034, it is the country the full report breaks out in detail.

Demand in Saudi Arabia follows the product type mix reported at global level: Cryopreservation Media is the largest line at 32% of 2025 revenue, moving to 33% by 2034, while Cryobags / Freezing Bags grows fastest at 13.52% and takes its share from 14% to 17%. Since 33.3% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Saudi Arabia by product type separately.

In Saudi Arabia, the Saudi Food and Drug Authority regulates cell cryopreservation consumables under its medical device framework, requiring an establishment licence and product registration before marketing. Classification follows a risk-based system aligned with the wider Gulf Cooperation Council approach to medical devices, and a supplier must demonstrate conformity with recognised international standards for device safety and quality management as part of registration. Products intended for use with human cells or tissue for therapeutic purposes attract additional scrutiny tied to the country's rules on cell and tissue handling. Labelling must be presented in Arabic alongside English, state storage and handling instructions, and identify the local authorised representative responsible for the product once it is placed on the market.

Competition in Saudi Arabia runs between the suppliers this study tracks: Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Sartorius AG, BioLife Solutions, Inc., Corning Incorporated, STEMCELL Technologies Inc., Lonza Group Ltd., Cytiva (Danaher Corporation), Takara Bio Inc., FUJIFILM Irvine Scientific, Inc., PromoCell GmbH, Saint-Gobain Life Sciences, Charter Medical, Ltd., OriGen Biomedical, Inc., Macopharma S.A., Avantor, Inc., Cardinal Health, Inc., HiMedia Laboratories Pvt. Ltd., Pluristyx, Inc., Cook Regentec LLC, Instant Systems, Inc., American Fluoroseal Corporation and GE HealthCare Technologies Inc.. Cryopreservation Media, at 32% of 2025 revenue, is where the volume sits, and Cryobags / Freezing Bags, growing at 13.52%, is where position changes hands over the forecast period. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.15 billion in 2025 reaching USD 0.47 billion by 2034, 3% of global revenue at the start of that period.

0.6% of global revenue is generated in South Africa; USD 0.03 billion in 2025, reaching USD 0.09 billion in 2034, and 20% of Middle East and Africa.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product type, cryoprotectant type, container material, fill volume / capacity, product grade, application / cell type, end user, sales / distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.